EPRX News & Events

The Company had cash and cash equivalents of $58.5M and short-term investments of $80.4M as of March 31, up from a cash balance of $80.6M at the end of the Q4 of 2025. These funds are being used to fund clinical trials in EP-104GI and the remainder of the funds will be used for general and administrative expenses, working capital needs and other general corporate purposes. "The clinical data reported this quarter further reinforces the potential for EP-104GI to become an important new treatment for Eosinophilic Esophagitis," said James A. Helliwell, CEO of Eupraxia. "With the capital from the recent financing, we are excited to continue development of EP-104GI in EoE and accelerate additional clinical programs in new indications within the GI field, where we believe that EP-104GI has the opportunity to work due to the Diffusphere's ability to provide hyper-targeted delivery into diseased areas over a long period of time without the typical systemic exposure profile."

Eupraxia Pharmaceuticals announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer as well as the retirement of Dr. Mark Kowalski, Eupraxia's current CMO. Dr. Jeymi Tambiah is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas' Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.

Eupraxia Pharmaceuticals announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the Resolve trial evaluating EP-104GI for the treatment of eosinophilic esophagitis, EoE. At 36 weeks, patients in Cohort 9 demonstrated a "robust" response in both tissue health and symptom response compared to their baseline levels. Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the Resolve trial. Clinical remission in symptoms was maintained in 66% of the patients in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks. EP-104GI continues to be well tolerated by patients receiving the drug; 31 patients have been treated in the Phase 1b/2a study and over 230 patient-months of follow-up have been reported with no drug related Serious Adverse Events. There still have been no cases of oropharyngeal candidiasis, a commonly reported adverse event with the oral delivery of steroids.